AINewsnow

Every Cure Partners with OpenEvidence to Advance Noncommercial Drug Repurposing

This story is from 2026-11-16. It is preserved in the archive; the latest stories are on the live feed.

On November 16, 2026, Every Cure announced a partnership with OpenEvidence to advance new uses for existing medicines where commercial incentives are lacking, linking AI-supported drug evaluation with repurposing efforts.

Read the full story at Unite.AI ↗

Timeline · 1 report

  1. 2026-11-16 19:21 · Unite.AI
    Every Cure Taps OpenEvidence to Advance Noncommercial Drug Repurposing

More stories

  1. OpenEvidence CEO says medical students should take paper exams despite AI — The Next Web
  2. OpenEvidence CEO says medical students should 'learn the hard way' amid AI reliance — Semafor Technology
  3. Apple Partners With OpenEvidence on Study of AI Use for Health Questions — AI Insider
  4. OpenAI launches GPT-6.2 Astra and Sol as Google ships Gemini 4 Neon and Microsoft unveils MAI Code 2 — OpenAI News
  5. Anthropic debuts on Nasdaq with record $81.3 billion IPO, hitting $2 trillion value — Anthropic (X)
  6. Google launches Gemini 4 Neon and opens Genie 4 world model to Gemini API developers — Google DeepMind YouTube
  7. Google books Blue Origin's New Glenn for 2029 launch of AI server satellites — Google: The Keyword
  8. AWS expands SageMaker AI with data preparation tools and cross-Region inference routing — AWS Machine Learning Blog

Read the Daily Brief: the day's most important AI stories →